TFA
TCRR

Toth Financial Advisory’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Toth Financial Advisory’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50
Closed – – 838
2021
Q3 		$0 Hold
50
– – ﹤0.01% 812
2021
Q2 		$1K Hold
50
– – ﹤0.01% 679
2021
Q1 		$1K Buy
+50
New +$1.36K ﹤0.01% 663
2020
Q4 		– Sell
-150
Closed -$3K – 638
2020
Q3 		$3K Hold
150
– – ﹤0.01% 462
2020
Q2 		$2K Hold
150
– – ﹤0.01% 486
2020
Q1 		$1K Hold
150
– – ﹤0.01% 445
2019
Q4 		$2K Hold
150
– – ﹤0.01% 443
2019
Q3 		$2K Buy
+150
New +$2.34K ﹤0.01% 437

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Toth Financial Advisory's TCRR Position: Q4 2021 in Review

Toth Financial Advisory sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 50 shares.

Toth Financial Advisory first reported a position in TCRR in Q3 2019 and held it in 8 quarters. The position peaked at $3K in Q3 2020. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

  • Toth Financial Advisory reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Toth Financial Advisory sold 50 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021.
  • Toth Financial Advisory first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2019 and held it in 8 quarters.
  • Toth Financial Advisory's TCR2 Therapeutics Inc. Common Stock position peaked at $3K in Q3 2020.
  • 122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on Toth Financial Advisory's 13F filing for Q4 2021, filed 31 Jan 2022.